GLP-1 Drug Exenatide Rescues Spinal Cord Damage in Diabetic Rats by Reducing Inflammation and Cell Death | Research

The takeaway

Two weeks of exenatide treatment reversed most of the structural, functional, and molecular damage to the spinal cord caused by type 2 diabetes in rats, including pain sensitivity, inflammation, oxidative stress, and neuronal death.

Most spinal cord impairments restored in 2 weeks
Exenatide reversed inflammation (IL-1β, NF-κB), oxidative stress (MDA, SOD), apoptosis (caspase-3, Bcl-2), and neurotrophic factor loss (NGF, GDNF) in diabetic rat spinal cords

What the researchers found

Diabetic rats showed comprehensive spinal cord disruption:

- Behavioral: thermal hyperalgesia, mechanical allodynia, decreased locomotor activity

- Metabolic: increased glucose, insulin, HbA1c, HOMA-IR; decreased insulin sensitivity

- Inflammatory: increased IL-1β, NF-κB; decreased IL-10 and β-endorphin in spinal tissue

- Oxidative: increased MDA; decreased SOD activity

- Apoptotic: upregulated caspase-3 and Bax; downregulated Bcl-2

- Neurotrophic: downregulated NGF and GDNF

- Histological: structural changes, increased CD68+ microglia

Exenatide treatment (10 μg/kg SC twice daily for 2 weeks) restored most of these biomolecular, structural, and functional impairments, demonstrating comprehensive neuroprotection.

Why it matters

Diabetic neuropathy affects up to 50% of diabetic patients and is a leading cause of disability, pain, and reduced quality of life. Current treatments only manage pain without addressing the underlying nerve damage. This study shows that exenatide — already FDA-approved for diabetes — can actually rescue spinal cord tissue from diabetic damage through multiple protective mechanisms. If these results translate to humans, GLP-1 drugs could treat both the diabetes and its neuropathic complications simultaneously.

How the study worked

30 male rats in three groups: control, diabetic (high-fat diet 8 weeks + streptozotocin 25 mg/kg IP), and diabetic + exenatide (10 μg/kg SC twice daily for 2 weeks). Assessments included neurobehavioral sensory/motor tests, glycemic biomarkers, spinal cord histology and immunohistochemistry, tissue cytokine and oxidant/antioxidant measurements (ELISA), and RT-qPCR for apoptotic and neurotrophic gene expression.

What this study cannot tell us

Preclinical rat study — results may not translate directly to human diabetic neuropathy. The STZ diabetes model is chemically induced and may not fully represent human T2DM neuropathy. Only 2 weeks of treatment in an acute model; human neuropathy develops over years. The 10-rat-per-group sample is small. Only exenatide was tested; other GLP-1RAs might differ. The degree to which spinal cord changes versus peripheral nerve changes drive symptoms was not distinguished.

How to read the evidence

Preclinical animal study with comprehensive multi-level analysis (behavioral, histological, immunohistochemical, biochemical, and molecular). The breadth of analysis is a strength, but the small sample, short treatment duration, and chemically-induced diabetes model limit translational conclusions.

When this study was published

Published in 2022, this study contributes to the expanding body of evidence for GLP-1RA neuroprotection, a field that continues to grow with ongoing clinical trials in neurological conditions.

The bigger picture

This study extends the neuroprotective profile of GLP-1 drugs from the brain (Alzheimer's, Parkinson's) to the spinal cord. The comprehensive nature of the protection — addressing inflammation, oxidative stress, cell death, and neurotrophic factor depletion simultaneously — suggests GLP-1 receptor activation triggers a broad neuroprotective program. The restoration of β-endorphin (an endogenous opioid peptide) in the spinal cord is particularly interesting as it may explain the pain-relieving effects.

Questions still open

Would longer-term GLP-1RA treatment prevent rather than reverse diabetic spinal cord damage?
Do patients on GLP-1RAs for diabetes already experience lower rates of neuropathy development?
Is the β-endorphin restoration a significant mechanism for the pain relief observed?

Common questions

How does diabetes damage the spinal cord?

Diabetes causes damage through multiple mechanisms: high blood sugar triggers inflammation and oxidative stress (free radical damage) in nerve tissue, activates cell death pathways, and reduces the growth factors nerves need to survive and repair themselves. This study found all of these processes occurring throughout the spinal cord in diabetic rats, contributing to increased pain sensitivity and reduced mobility.

Could GLP-1 drugs like Ozempic help with diabetic nerve pain?

This animal study suggests they might. Exenatide (a GLP-1 drug related to semaglutide/Ozempic) reversed much of the spinal cord damage and pain sensitivity caused by diabetes in rats. If these effects occur in humans, patients taking GLP-1 drugs for diabetes might also experience reduced neuropathic pain. However, this hasn't been confirmed in clinical trials yet.

Read the original research

Spinal cord-wide structural disruption in type 2 diabetes rescued by exenatide "a glucagon-like peptide-1 analogue" via down-regulating inflammatory, oxidative stress and apoptotic signaling pathways.

Journal of chemical neuroanatomy, 121, 102079

View on PubMed ↗Publisher’s paper ↗

Citation

Mandour, Dalia A; Shalaby, Sally M; Bendary, M A. (2022). Spinal cord-wide structural disruption in type 2 diabetes rescued by exenatide "a glucagon-like peptide-1 analogue" via down-regulating inflammatory, oxidative stress and apoptotic signaling pathways.. Journal of chemical neuroanatomy, 121, 102079. https://doi.org/10.1016/j.jchemneu.2022.102079